Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

By Yahoo! Finance | Oct 29, 2024 at 02:46 PM EST

Coya Therapeutics reported positive results from a Phase 2 trial of LD IL-2 for Alzheimer's at CTAD24. The study met primary and secondary endpoints, showing safety and efficacy. The q4wks dosing led to significant improvements in CSF Aβ42 levels.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.